Auxilium Pharmaceuticals Inc

Auxilium Pharmaceuticals — Investor Presentation (February 2008)

35 slides from Auxilium Pharmaceuticals's investor presentation, Feb 28, 2008

  1. Slide 1: February 2008

    Exhibit 99.1 February 2008

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to ma

  3. Slide 3: Fastest Growing TRT Product, Late Stage Company, Transforming Product

    Fastest Growing TRT product in the U.S. Late Stage Company Transforming Product Poised for Growth + =

  4. Slide 4: Auxilium Pharmaceuticals, Inc.

    Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) • Specialty biopharmaceutical company focused on Urologists, Endocrinologists, Orthopedists and certain PCPs • Founded in 1999 • Headquarters in Malvern, Pa. – Manufacturing in Horsham, Pa. – Approximately 29

  5. Slide 5: Broad Pipeline Maturing in Coming Years

    Broad Pipeline Maturing in Coming Years 6 Market Phase III Phase II Phase I Hypogonadism Dupuytren’s Contracture Peyronie’s Disease Frozen Shoulder Syndrome Overactive Bladder Broad Pipeline Maturing in Coming Years Note: Worldwide rights for all products available, except Testim where ex -U.S. righ

  6. Slide 6: Anticipated News Flow Events

    Anticipated News Flow Events 5 6 6 Q409 Q309 Q209 Q109 Early 2010 Anticipated News Flow Events Jan 22: • Testim- Patent Issued Q108/Q208: • XIAFLEX- Complete Peyronie's Animal Study • XIAFLEX- Initiate Peyronie's Phase IIb Studies Q208: • XIAFLEX- Top - line Phase III (Double Blind) Data H109: • XIA

  7. Slide 7: XIAFLEX: A Company Transforming Opportunity

    XIAFLEX™ (clostridial collagenase for injection) A Company Transforming Opportunity

  8. Slide 8: XIAFLEX – Company Transforming Opportunity

    XIAFLEX – Company Transforming Opportunity XIAFLEX – Company Transforming Opportunity • Potential to replace surgery in certain indications • Great fit for Specialty Biopharmaceutical Company • Worldwide rights offer options to build company or generate cash – exploring partnering opportunities now

  9. Slide 9: XIAFLEX for Dupuytren's Contracture

    XIAFLEX for Dupuytren’s Contracture XIAFLEX for Dupuytren’s Contracture • Collagen accumulation in hand causes affected fingers to become permanently flexed Disease description • Patented through 2014; Orphan Drug Exclusivity for 7 years post approval I.P. position • Surgery is only approved treatme

  10. Slide 10: Potential to Revolutionize Treatment for Dupuytren's Contracture

    Potential to Revolutionize Treatment for Dupuytren’s Contracture Current Treatment Potential to Revolutionize Treatment for Dupuytren’s Contracture XIAFLEX Treatment

  11. Slide 11: Journal of Hand Surgery, July/Aug 2007 - Methods

    Journal of Hand Surgery , July/Aug 2007- Methods Journal of Hand Surgery , July/Aug 2007- Methods • Randomized, double-blind, placebo controlled • 35 Patients (28 men, 7 women) • Mean Age was 61 ± 8.5 years • XIAFLEX Injections: – 10,000 units dosing – Maximum 3 injections per joint at 4-6 week inte

  12. Slide 12: Pivotal Phase III Study – Results

    Pivotal Phase III Study – Results Pivotal Phase III Study – Results XIAFLEX Placebo P-value Primary End Point 21/23 (91%)* < .001 - MP Joint 12/14 (86%) < .001 - PIP Joint 9/9 (100%) < .001 Secondary Joint 5/6 (83%) .035 Median Time to Success 8 Days N/A Mean # Injections For Success 1.4 N/A * Succe

  13. Slide 13: Pivotal Phase III Study – Other Findings

    Pivotal Phase III Study – Other Findings Pivotal Phase III Study – Other Findings • Adverse Events: – No Serious Adverse Events reported – Adverse events were mild to moderate, mostly local reactions. Resolved within a mean of 3 weeks – No reports of loss of sensation or infections, and no skin graf

  14. Slide 14: Dupuytren's Clinical Plan ~725 total patients

    Dupuytren’s Clinical Plan ~ 725 total patients Dupuytren’s Clinical Plan ~ 725 total patients • CORD I Study: – 216 patients in at least 15 sites in the U.S. – Double blind placebo controlled, randomized in 2:1 ratio of active to placebo – Primary endpoint is reduction in contracture to within 0 - 5

  15. Slide 15: Dupuytren's Commercial Opportunity

    Dupuytren’s Commercial Opportunity We believe: • There is a pent-up demand for non-surgical therapy • Surgeons and patients prefer non-invasive treatment • Each patient on average has 2.2 joints which will require treatment; 49% have contractures in both hands • Early data indicates on average 1.4 v

  16. Slide 16: Market Research Performed – Dupuytren's

    Market Research Performed – Dupuytren’s Market Research Performed – Dupuytren’s • Multiple prevalence data sets proved to be highly variable in numbers of patients • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Dupuytren’s contracture • A combined 571

  17. Slide 17: 240,000 Dupuytren's Candidates In U.S. & Europe Annually

    240,000 Dupuytren’s Candidates In U.S. & Europe Annually Patients Seeking Treatment ~1,030,000 No Prior Surgery ~540,000 Had Surgery Previously ~490,000 Watchful Waiting ~270,000 Medical/ Surgical Treatment ~270,000 Medical/ Surgical Treatment ~125,000 Watchful Wait/ In Follow Up ~365,000 XIAFLEX Po

  18. Slide 18: XIAFLEX for Peyronie's Disease

    XIAFLEX for Peyronie’s Disease XIAFLEX for Peyronie’s Disease • Patented through 2019 • Orphan Drug exclusivity for 7 years post approval I.P. position • Treated by urologists • Lacks good treatment options – PABA, Vitamin E, Verapamil ineffective – Surgery may shorten penis; cause scarring • Unmet

  19. Slide 19: Peyronie's Clinical Plan

    Peyronie’s Clinical Plan Peyronie’s Clinical Plan • Local effects / tolerability pre-clinical study outside of plaque requested by FDA. In life stage of animal study completed 4Q 2007. Expect to send final report to FDA in 1H 2008. • Phase IIb dose ranging study expected to begin in Q2 2008, pending

  20. Slide 20: Market Research Performed – Peyronie's

    Market Research Performed – Peyronie’s Market Research Performed – Peyronie’s • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Peyronie’s disease • A combined 575 Urologists have been interviewed to estimate market size (415 in U.S.; 160 in Europe) and

  21. Slide 21: 210,000 Peyronie's Candidates In U.S. and Europe Annually

    210,000 Peyronie’s Candidates In U.S. and Europe Annually Patients Seeking Treatment ~475,000 Surgery Not Recommended ~365,000 Watchful Waiting ~160,000 Medical or Intralesional Therapy ~205,000 Surgery Recommended ~110,000 XIAFLEX Potential Candidates ~210,000 210,000 Peyronie’s Candidates In U.S.

  22. Slide 22: XIAFLEX for Frozen Shoulder Syndrome

    XIAFLEX for Frozen Shoulder Syndrome XIAFLEX for Frozen Shoulder Syndrome • Arthroscopic procedure or surgery Current treatment • Early studies showed trend to efficacy and tolerability at highest dose (10,000 units) • Additional phase II studies needed to assess optimal dose, primary endpoints and

  23. Slide 23: Testim 1% Testosterone Gel: Near-Term Growth Driver

    Testim ® 1% Testosterone Gel: Near-Term Growth Driver Executing on Opportunities

  24. Slide 24: Testim is the Fastest Growing Testosterone Replacement Therapy Gel

    Testim ® is the Fastest Growing Testosterone Replacement Therapy Gel Testim ® is the Fastest Growing Testosterone Replacement Therapy Gel • Proprietary, topical 1% testosterone gel – Once-a-day application – Favorable clinical and commercial profile • Comparative studies support advantages • Non-sub

  25. Slide 25: Male Hypogonadism (Testosterone Deficiency) Overview

    Male Hypogonadism (Testosterone Deficiency) Overview Male Hypogonadism (Testosterone Deficiency) Overview • Recent study indicates 39% of U.S. males over 45 yrs are hypogonadal – We estimate that less than 10% of affected population receives treatment • Diagnosis increasing through education and awa

  26. Slide 26: Clinical Results Show Testim Changes Body Composition

    Clinical Results Show Testim ® Changes Body Composition Improves Sexual Activity Clinical Results Show Testim ® • Sexual Activity 59% • Statistically significant increases in sexual desire • Lean Body Mass 4.8 lbs • Fat Mass 4.0 lbs • Bone Mineral Density 2.6 % 12-month study Placebo-controlled stud

  27. Slide 27: 447% +30%

    447% +30%

  28. Slide 28: Gels Fastest Growing TRT Segment

    Gels Fastest Growing TRT Segment Gels Fastest Growing TRT Segment Source: IMS data ($ in millions) Gel Patch Oral Injectables $35 $117 $200 $287 $340 $383 $449 $459 $399 $302 $210 $77 $59 $49 $499 $118 $568 Gel Segment Growth ($) Dec 2007 L12M: +25% Gel Segment Growth ($) Gel Segment Growth ($) Dec

  29. Slide 29: Testim Established Track Record of Consistent Growth

    Testim ® quarterly net revenues and scripts Established Track Record of Consistent Growth $- $5 $10 $15 $20 $25 $30 Net Revs TRX ® ($ in millions) Established Track Record of Consistent Growth Q4 2007 Net Revenues Y/Y Growth: +40% Q4 2007 Net Q4 2007 Net Revenues Revenues Y/Y Growth: Y/Y Growth: +40

  30. Slide 30: Testim Driving Growth in Market

    Testim ® Driving Growth in Market Testim ® Share of TRx of Gel Market Testim ® Driving Growth in Market Source: IMS data Strong market share with high-prescribing urologists & PCP’s; 39.2% gel market share of decile 8-10 Urologists and 29% share with decile 8 – 10 PCP’s in December 2007 1.0% 21.5% 0

  31. Slide 31: Testim Patent Coverage

    Testim Patent Coverage • U.S. Testim ® patent (covering Hsieh Enhancers) expires in June 2008 • U.S. Patent # 7,320,968 covering method of use claims for Testim issued January 22, 2008; expires 2025 • Divisional application and continuations filed with USPTO in late 2007 with a plan to protect addit

  32. Slide 32: Financials / Strategic Priorities

    Financials / Strategic Priorities

  33. Slide 33: 2007 Financial Results and 2008 Guidance

    2007 Financial Results and 2008 Guidance ($ Millions) YTD Q4 ’07 Dec ’07 Guidance Revenues $27.7 $95.7 $120-125 R&D Expense $14.5 $42.8 $52-56 SG&A Expense $18.9 $72.8 $88-92 Net Loss $11.9 $40.7 $44-48 Stock – Based Comp Expense $1.8 $6.0 $9-11 Cash & short term investments $76.1 2007 Financial Res

  34. Slide 34: Strategic Priorities

    Strategic Priorities Strategic Priorities • Continue Development of XIAFLEX with a plan to: – Complete dosing in CORD I and double blind portion of CORD II in Q1 2008, allowing for top line results to be announced in Q2 2008 & be prepared to file BLA in early – Initiate Phase IIb in Peyronie’s Disea

  35. Slide 35: Fastest Growing TRT Product, Late Stage Company

    Fastest Growing TRT product in the U.S. Late Stage Company Transforming Product Poised for Growth + =

Auxilium Pharmaceuticals — Investor Presentation (February 2008) on 6ix